Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

A PHASE 1/2, OPEN-LABEL, SINGLE ARM TRIAL TO DETERMINE THE RECOMMENDED PHASE 2 DOSE AND EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS IN KOREA WITH KRAS WILD TYPE ADVANCED NSCLC, WHICH IS REFRACTORY TO CHEMOTHERAPY AND ERLOTINIB OR GEFITINIB

To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.

Inclusion Criteria:

• Advanced NSCLC
• Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib
• Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment
• Measurable disease

Exclusion Criteria:

• Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of baseline disease assessment
• Patients who lack of tolerance of erlotinib therapy
• Patients with known brain Metastases
• Patients with demonstrated history of or presence of interstitial lung disease.